USANA Health Sciences (NYSE:USNA) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why

USANA Health Sciences, Inc. (NYSE:USNA)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $19.41 and traded as high as $21.40. USANA Health Sciences shares last traded at $21.15, with a volume of 144,191 shares.

Analyst Upgrades and Downgrades

USNA has been the subject of a number of recent research reports. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

USANA Health Sciences Price Performance

The company’s 50-day moving average is $18.97 and its two-hundred day moving average is $19.42. The firm has a market cap of $401.63 million, a P/E ratio of 46.29, a PEG ratio of 0.83 and a beta of 0.76.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.44 by $0.17. The firm had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, analysts expect that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Insider Activity

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares in the company, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $19.82, for a total value of $75,137.62. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 17,660 shares of company stock valued at $336,579. 0.82% of the stock is owned by insiders.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of USNA. Nantahala Capital Management LLC bought a new position in USANA Health Sciences in the fourth quarter valued at about $11,485,000. Millennium Management LLC lifted its holdings in shares of USANA Health Sciences by 715.7% in the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after acquiring an additional 250,424 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of USANA Health Sciences by 349.8% in the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after purchasing an additional 125,158 shares in the last quarter. UBS Group AG boosted its stake in shares of USANA Health Sciences by 252.3% in the 4th quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after purchasing an additional 99,063 shares in the last quarter. Finally, Tudor Investment Corp ET AL grew its holdings in shares of USANA Health Sciences by 354.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after purchasing an additional 85,570 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.